Sotalol for paroxysmal supraventricular tachycardias.
Used in adequate dosages, sotalol is efficacious in the conversion of acute supraventricular arrhythmias, an effect that is predictable on the basis of the drug's known electropharmacologic actions. Electrophysiologic studies have shown that both oral and intravenous sotalol are effective in preventing the induction of sustained arrhythmias and that the success of acute suppression is indicative of subsequent clinical control. Interim results of a recent trial of prophylaxis against recurrence of paroxysmal supraventricular tachycardia are reported, demonstrating a high efficacy with an acceptably low profile of adverse effects.
Department of Cardiological Sciences, St. George's Hospital Medical School, London, United Kingdom.
A J
AJ
Camm
V
V
Paul
D004311:Double-Blind Method; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013015:Sotalol / Q000008:administration & dosage / Q000627:therapeutic use*; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy* / Q000503:physiopathology; D013617:Tachycardia, Supraventricular / Q000188:drug therapy* / Q000503:physiopathology
D013015:Sotalol